alprolix 3000 i.u powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - eftrenonacog alfa - powder and solvent for solution for injection - 3000 iu
elocta 3000 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 3000 iu
alprolix 250 i.u powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - eftrenonacog alfa - powder and solvent for solution for injection - 250 iu
elocta 250 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 250 iu
elocta 2000 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 2000 iu
elocta 1500 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 1500 iu
elocta 1000 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 1000 iu
elocta 500 iu powder for solution for injection powder and solvent for solution for injection
swedish orphan biovitrum international ab, sweden - efmoroctocog alfa - powder and solvent for solution for injection - 500 iu
kineret solution for injection
swedish orphan biovitrum international ab, sweden - anakinra - solution for injection - 150 mg/ml,
zynlonta
swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastic agents - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.